Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

Por Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Publicado no Onco Targets Ther (2015)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

Por Sato, Yasuyoshi, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Publicado no Onco Targets Ther (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

Por Ohhara, Yoshihito, Suenaga, Mitsukuni, Matsusaka, Satoshi, Shinozaki, Eiji, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients

Por OSUMI, HIROKI, MATSUSAKA, SATOSHI, WAKATSUKI, TAKERU, SUENAGA, MITSUKUNI, SHINOZAKI, EIIJ, MIZUNUMA, NOBUYUKI
Publicado no Mol Clin Oncol (2015)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Yamaguchi, Toshiharu
Publicado no Drug Des Devel Ther (2015)

UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal...

Por Miyata, Yoshinori, Touyama, Tetsuo, Kusumi, Takaya, Morita, Yoshitaka, Mizunuma, Nobuyuki, Taniguchi, Fumihiro, Manabe, Mitsuaki
Publicado no Int J Clin Oncol (2015)

A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction

Por SUZUKI, SHUN-ICHI, MATSUSAKA, SATOSHI, HIRAI, MITSUHARU, SHIBATA, HARUMI, TAKAGI, KOICHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado no Int J Oncol (2015)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Shinozaki, Eiji, Matsusaka, Satoshi, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Publicado no Drug Des Devel Ther (2015)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report

Por Osumi, Hiroki, Matsusaka, Satoshi, Shinozaki, Eiji, Suenaga, Mitsukuni, Mingyon, Mun, Saiura, Akio, Ueno, Masashi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado em 2013

In vitro selection of an RNA sequence that interacts with high affinity with thymidylate synthase

Por Lin, Xiukun, Mizunuma, Nobuyuki, Chen, Tian-men, Copur, Sitki M., Maley, Gladys F., Liu, Jun, Maley, Frank, Chu, Edward
Publicado em 2000

Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of...

Por OBA, MASARU, CHIN, KEISHO, KAWAZOE, YOSHIMASA, TAKAGI, KOICHI, OGURA, MARIKO, SHINOZAKI, EIJI, SUENAGA, MITSUKUNI, MATSUSAKA, SATOSHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado em 2011

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

Por OBA, MASARU, CHIN, KEISHO, KAWAZOE, YOSHIMASA, TAKAGI, KOICHI, OGURA, MARIKO, SHINOZAKI, EIJI, SUENAGA, MITSUKUNI, MATSUSAKA, SATOSHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado em 2011

Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

Por KUBOKI, YASUTOSHI, MIZUNUMA, NOBUYUKI, OZAKA, MASATO, OGURA, MARIKO, SUENAGA, MITSUKUNI, SHINOZAKI, EIJI, MATSUSAKA, SATOSHI, CHIN, KEISHOU, MATSUURA, MASAAKI, HATAKE, KIYOHIKO
Publicado em 2011

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chem...

Por Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Kumekawa, Yosuke, Ogura, Mariko, Ozaka, Masato, Matsusaka, Satoshi, Chin, Keisho, Yamamoto, Noriko, Mizunuma, Nobuyuki
Publicado no BMC Cancer (2015)

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy

Por Matsusaka, Satoshi, Kobunai, Takashi, Yamamoto, Noriko, Chin, Keisho, Ogura, Mariko, Tanaka, Gotaro, Matsuoka, Kazuaki, Ishikawa, Yuichi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Genes Cancer (2016)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer

Por Doi, Toshihiko, Boku, Narikazu, Kato, Ken, Komatsu, Yoshito, Yamaguchi, Kensei, Muro, Kei, Hamamoto, Yasuo, Sato, Atsushi, Koizumi, Wasaburo, Mizunuma, Nobuyuki, Takiuchi, Hiroya
Publicado em 2010

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

Por Suenaga, Mitsukuni, Fujimoto, Yoshiya, Matsusaka, Satoshi, Shinozaki, Eiji, Akiyoshi, Takashi, Nagayama, Satoshi, Fukunaga, Yosuke, Oya, Masatoshi, Ueno, Masashi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Por Suenaga, Mitsukuni, Nishina, Tomohiro, Mizunuma, Nobuyuki, Yasui, Hisateru, Ura, Takashi, Denda, Tadamichi, Ikeda, Junichi, Esaki, Taito, Nishisaki, Hogara, Takano, Yoshinao, Sugiyama, Yasuyuki, Muro, Kei
Publicado no BMC Cancer (2015)

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

Por Kawakami, Kazuyoshi, Nakamoto, Eri, Yokokawa, Takashi, Sugita, Kazuo, Mae, Yutarou, Hagino, Akane, Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Oniyama, Sayaka, Machida, Yoshiaki, Yamaguchi, Toshiharu, Hama, Toshihiro
Publicado no Patient Prefer Adherence (2015)